Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small Cell Lung Cancer (NSCLC) accounts for 85% of lung cancer cases.
• Current targeted therapies, including Tyrosine Kinase Inhibitors (TKIs), show limited long-term efficacy, with a 5-year survival rate of 18%.
• Acquired resistance to therapy is a significant clinical problem, often linked to specific genetic mutations.

Purpose of the Study:

• To review key molecules involved in NSCLC pathogenesis.
• To discuss the mechanisms of treatment resistance in NSCLC.
• To highlight recent therapeutic advancements in NSCLC over the past decade.

Main Methods:

• Literature review of NSCLC molecular targets and resistance mechanisms.
• Analysis of common genetic alterations such as KRAS, EGFR, and ALK rearrangements.
• Examination of emerging therapies, including immunotherapy.

Main Results:

• KRAS and EGFR mutations are prevalent in lung adenocarcinoma (25% and 20%, respectively).
• ALK rearrangements occur in 3-7% of NSCLC, mutually exclusive with KRAS/EGFR mutations.
• The T790M mutation in EGFR is found in nearly half of drug-resistant NSCLC patients.

Conclusions:

• Understanding NSCLC molecular drivers and resistance mechanisms is crucial for effective treatment.
• Recent advances, particularly in immunotherapy (PD-1/PD-L1), offer new hope for NSCLC patients.
• Continued research into targeted therapies and combination strategies is essential to improve patient outcomes.